The results of the randomized clinical trial, published October 22, 2019 in JAMA, found that a commonly prescribed SSRI medication for children and adolescents with autism, is no more effective than a placebo at treating obsessive-compulsive behaviors.
At first, the Prozac (fluoxetine) group appeared to show a slight lessening of obsessive-compulsive symptoms after the 16 weeks of treatment when compared with the placebo. However, after the researchers controlled for potenially confounding factors including age, sex and the severity of symptoms at the start of the trial, they found that there was no difference between the treatment and control groups. The group that received the Prozac did no better than the placebo and the obsessive-compulsive behaviors remained. In general, many children with ASD have anxiety and OCD symptoms.
The results of this current 2019 research, which is a randomized clinical trial, added further support to 2004 research, 2008 research, 2009 research, 2019 research that found none to mixed results for pharmacological interventions for those with autism. The findings in this 146- participant study, are consistent with other research, which demonstrates the inconclusive efficacy of SSRIs for those with ASD at best.
The researchers noted, “Published reports indicate that more than half of children and adolescents with ASDs are prescribed medication, with 21% to 32% receiving selective serotonin receptor inhibitors (SSRIs) despite inconclusive evidence for their efficacy”
So why is it still prescribed so much? Autism is a complex disorder with multiple reasons why it happens; none of which we really fully understand how these multiple factors interact and directly cause autism. Unfortunately, like so many disorders there is a constant push to find that magic pill that is going to fix it. We know that autism doesn’t result from a specific biochemical or genetic issue, so a different approach needs to be taken.
Parents need to know that they can reduce and reverse symptoms following a more holistic route that uses evidence-based therapies. At our Ridgefield, CT center and our upcoming home study parent course, we focus on teaching parents about root causes and how they have the power to help their own children.
Our symptom reversal plan focuses on:
The pairing of brain-based therapies, such as neurofeedback, biofeedback, and psychotherapy with support for the body has helped thousands of clients become calmer, more flexible, more focused, better able to communicate with others, and just feel more even in their mood.
Call our center today to discuss how we can help you or your child with our clinically effective and natural therapies, such as neurofeedback or biofeedback, addressing Autism, ADHD, anxiety, depression, and numerous other conditions. We also offer counseling, executive functioning coaching and behavioral support for children and families, and parent coaching sessions with our staff psychotherapists. To set up an appointment for a consultation with Dr. Roseann, or to meet with one of our psychotherapists,
call 203.438.4848 or email: firstname.lastname@example.org.
Dr. Roseann is a Psychologist and Therapist and our center provides expert-level care for children, adults, and families from all over the US, supporting them with research-based and holistic therapies that are bridged with neuroscience. She is a Dr. Roseann is a Board Certified Neurofeedback (BCN) Practitioner, a Board Member of the Northeast Region Biofeedback Society (NRBS) and Epidemic Answers, Certified Integrative Medicine Mental Health Provider (CMHIMP) and an Amen Clinic Certified Brain Health Coach. She is also a member of The International Lyme Disease and Associated Disease Society (ILADS), The American Psychological Association (APA), National Association of School Psychologists (NASP), Connecticut Counseling Association (CCA), International OCD Foundation (IOCDF) International Society for Neurofeedback and Research (ISNR) and The Association of Applied Psychophysiology and Biofeedback (AAPB).
©Roseann-Capanna-Hodge, LLC 2019